Uno studio per valutare la sicurezza e l'efficacia di A2B395, un CAR T allogenico con logica logica, in partecipanti con tumori solidi che esprimono EGFR e hanno perso l'espressione HLA-A*02 (DENALI-1)
Uno studio di fase 1/2 senza soluzione di continuità per valutare la sicurezza e l'efficacia di A2B395, un CAR T Tmod™ allogenico con logica logica, in adulti eterozigoti HLA-A*02 con tumori solidi ricorrenti non resecabili, localmente avanzati o metastatici che esprimono EGFR e presentano Espressione HLA-A*02 persa
The goal of this study is to test A2B395, an allogeneic logic-gated Tmod™ CAR T-cell product in subjects with solid tumors including colorectal cancer (CRC), non-small cell lung cancer (NSCLC), head and neck squamous cell carcinoma (HNSCC), triple-negative breast cancer (TNBC), renal cell carcinoma (RCC) and other solid tumors that express EGFR and have lost HLA-A*02 expression.
The main questions this study aims to answer are:
- Phase 1: What is the recommended dose of A2B395 that is safe for patients
- Phase 2: Does the recommended dose of A2B395 kill the solid tumor cells and protect the patient's healthy cells
Participants will be required to perform study procedures and assessments, and will also receive the following study treatments:
- Enrollment in BASECAMP-1 (NCT04981119)
- Preconditioning lymphodepletion (PCLD) regimen
- A2B395 Tmod CAR T cells at the assigned dose
Panoramica dello studio
Stato
Stato
Condizioni
Condizioni
- Cancro ai reni
- Carcinoma a cellule renali
- Cancro
- Cancro colorettale
- Cancro ai polmoni
- Cancro rettale
- Cancro al seno triplo negativo
- Cancro al colon
- Tumore a cellule squamose della testa e del collo
- Adenocarcinoma colorettale
- Tumore solido, adulto
- CRC
- HNSCC
- TNBC
- RCC
- NSCLC (carcinoma polmonare non a piccole cellule)
- Polmone non a piccole cellule
Intervento / Trattamento
Intervento / Trattamento
Descrizione dettagliata
This is a seamless phase 1/2, multi-center, open-label study that enrolls adults with recurrent unresectable, locally advanced, or metastatic (considered non-curative) CRC, NSCLC, HNSCC, TNBC, RCC, or other solid tumors with EGFR expression. Subjects must be germline HLA-A*02 heterozygous, with tumors that express EGFR and have lost HLA-A*02 expression. The purpose of Phase 1 of this study is to determine the safety and the optimal dose of A2B395 (after PCLD) in participants with solid tumor disease. The purpose of Phase 2 of this study is to determine the further safety and efficacy (how well it treats the solid tumor disease) of A2B395.
The treatment available for these cancers and other solid tumors can be toxic, debilitating, and fatal. In the recurrent unresectable, locally advanced, or metastatic setting, the intent of standard of care treatment is typically palliative rather than curative, and has not changed significantly in several decades. A2 Bio hypothesizes that A2B395 Tmod CAR T-cell therapy will enable the killing of tumor target cells (those cells that express EGFR and have loss of heterozygosity [LOH] for the HLA-A*02 protein). Additionally, normal healthy cells that maintain HLA-A*02 expression and co-express EGFR (eg, skin tissue) will not be targeted due to the blocker portion of the Tmod CAR T cell that acts as a self-regulated safety switch that protects normal tissue from damage. Furthermore, the blocker portion of the Tmod CAR T cell will act as a safety switch to protect normal tissue from graft versus host disease (GvHD) that could be caused by an allogeneic CAR T cell. A2 Bio intends this to provide a wider therapeutic safety window compared to previous solid tumor targeting therapies. This hypothesis will be explored in the study.
Participants for this study must enroll and have confirmation of LOH in the pre-screening BASECAMP-1 study (NCT04981119). Upon disease progression the participant may screen for this study (DENALI-1). There is no time requirement between the studies, and patients may go directly from BASECAMP-1 to DENALI-1 based on their own disease course.
Tipo di studio
Tipo di studio
Iscrizione (Stimato)
Iscrizione
Fase
Fase
- Fase 2
- Fase 1
Contatti e Sedi
Luoghi di studio
-
-
Arizona
-
Gilbert, Arizona, Stati Uniti, 85234
- Banner MD Anderson Cancer Center
-
Phoenix, Arizona, Stati Uniti, 85054
- Mayo Arizona
-
-
California
-
La Jolla, California, Stati Uniti, 92093
- UCSD Moores Cancer Center
-
Los Angeles, California, Stati Uniti, 90404
- UCLA Medical Center
-
Palo Alto, California, Stati Uniti, 94304
- Stanford University
-
-
Florida
-
Jacksonville, Florida, Stati Uniti, 32224
- Mayo Clinic
-
Tampa, Florida, Stati Uniti, 33606
- Moffitt Cancer Center
-
-
Minnesota
-
Rochester, Minnesota, Stati Uniti, 55905
- Mayo Clinic
-
-
Missouri
-
St Louis, Missouri, Stati Uniti, 63110
- Washington University
-
-
New York
-
New York, New York, Stati Uniti, 10016
- NYU Langone Health
-
-
Ohio
-
Columbus, Ohio, Stati Uniti, 43210
- The Ohio State University
-
-
Tennessee
-
Nashville, Tennessee, Stati Uniti, 37232
- Vanderbilt-Ingram Cancer Center
-
-
Washington
-
Seattle, Washington, Stati Uniti, 98109
- Fred Hutch Cancer Center
-
-
Criteri di partecipazione
Criteri di ammissibilità
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Descrizione
Inclusion Criteria:
Key Inclusion Criteria:
- Appropriately enrolled in the BASECAMP-1 A2 Biotherapeutics, Inc. study, with tissue demonstrating LOH of HLA-A*02 by NGS (whenever possible from the primary site).
- Histologically confirmed recurrent unresectable, locally advanced, or metastatic CRC, NSCLC, HNSCC, TNBC, RCC, or other solid tumors with EGFR expression. Measurable disease is required with lesions of ≥1.0 cm by CT.
- Received previous required therapy for the appropriate solid tumor disease as described in the protocol
- Has adequate organ function as described in the protocol
- ECOG performance status of 0 to 1
- Life expectancy of ≥3 months
- Willing to comply with study schedule of assessments including long-term safety follow-up
Key Exclusion Criteria:
- Has disease that is suitable for local therapy or able to receive standard of care therapy that is therapeutic and not palliative
- Prior allogeneic stem cell transplant
- Prior solid organ transplant
- Cancer therapy within 3 weeks or 3 half lives of A2B395 infusion
- Radiotherapy within 28 days of A2B395 infusion
- Unstable angina, arrhythmia, myocardial infarction, or any other significant cardiac disease within the last 6 months
- Any new symptomatic pulmonary embolism (PE) or a deep vein thrombosis (DVT) within 3 months of enrollment. Therapeutic dosing of anticoagulants is allowed for history of PE or DVT if greater than 3 months from time of enrollment, and adequately treated
- History of interstitial lung disease including drug-induced interstitial lung disease and radiation pneumonitis that requires treatment with prolonged steroids or other immune suppressive agents within 1 year
- Requires supplemental home oxygen
- Females of childbearing potential who are pregnant or breastfeeding
- Subjects, both male and female, of childbearing potential who are not willing to practice birth control from the time of consent through 6 months post infusion of A2B395
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Trattamento
- Assegnazione: N / A
- Modello interventistico: Assegnazione di gruppo singolo
- Mascheramento: Nessuno (etichetta aperta)
Numero di armi
Armi e interventi
Gruppo di partecipanti / ArmGruppo di partecipanti / Arm |
Intervento / TrattamentoIntervento / Trattamento |
|---|---|
|
Sperimentale: A2B395
Participants receive preconditioning lymphodepletion (PCLD) regimen followed by a single dose of A2B395 intravenously on day 0 |
Allogeneic logic-gated Tmod CAR T cells
Altri nomi:
An investigational next generation sequencing (NGS) in vitro diagnostic (IVD) medical device |
Cosa sta misurando lo studio?
Misure di risultato primarie
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Phase 1: Rate of adverse events and dose limiting toxicities (DLTs) by dose level
Lasso di tempo: From the time of Informed consent until 24 months (2 years) post A2B395 infusion
|
Adverse events and toxicity will be evaluated according to the Cancer Therapy Evaluation Program Common Terminology Criteria for Adverse Events (CTCAE) version 5.0 (or current version). Cytokine release syndrome (CRS), immune effector cell-associated neurotoxicity syndrome (ICANS), and graft versus host disease (GvHD) events will be graded according to the criteria described in the current protocol. |
From the time of Informed consent until 24 months (2 years) post A2B395 infusion
|
|
Phase 1: Recommended phase 2 dose (RP2D)
Lasso di tempo: 28 days post A2B395 infusion
|
The RP2D will be identified utilizing a BOIN study design in addition to considering safety and biomarker analysis. |
28 days post A2B395 infusion
|
|
Phase 2: The overall response rate (ORR) for patients
Lasso di tempo: 24 months post A2B395 infusion
|
The ORR will be evaluated per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 and assessed by independent central review. |
24 months post A2B395 infusion
|
Misure di risultato secondarie
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Persistence of A2B395
Lasso di tempo: up to 24 months post A2B395 infusion
|
Number of A2B395 Tmod CAR T cells present in participants treated with A2B395 as assessed by polymerase chain reaction (PCR) (or similar method) on participant blood samples |
up to 24 months post A2B395 infusion
|
|
Cytokine analysis
Lasso di tempo: up to 24 months post A2B395 infusion
|
Cytokine levels such as interferon-gamma (IFN-γ) in participants treated with A2B395 assessed by cytokine analysis on participant blood samples |
up to 24 months post A2B395 infusion
|
|
Cytokine analysis
Lasso di tempo: up to 24 months post A2B395 infusion
|
Cytokine levels such as interleukin-6 (IL-6) in participants treated with A2B395 assessed by cytokine analysis on participant blood samples |
up to 24 months post A2B395 infusion
|
Collaboratori e investigatori
Sponsor
Sponsor
Investigatori
Investigatori
- Direttore dello studio: John Welch, MD, PhD, A2 Biotherapeutics
Pubblicazioni e link utili
Pubblicazioni generali
- Hamburger AE, DiAndreth B, Cui J, Daris ME, Munguia ML, Deshmukh K, Mock JY, Asuelime GE, Lim ED, Kreke MR, Tokatlian T, Kamb A. Engineered T cells directed at tumors with defined allelic loss. Mol Immunol. 2020 Dec;128:298-310. doi: 10.1016/j.molimm.2020.09.012. Epub 2020 Oct 1.
- Hwang MS, Mog BJ, Douglass J, Pearlman AH, Hsiue EH, Paul S, DiNapoli SR, Konig MF, Pardoll DM, Gabelli SB, Bettegowda C, Papadopoulos N, Vogelstein B, Zhou S, Kinzler KW. Targeting loss of heterozygosity for cancer-specific immunotherapy. Proc Natl Acad Sci U S A. 2021 Mar 23;118(12):e2022410118. doi: 10.1073/pnas.2022410118.
- Beroukhim R, Mermel CH, Porter D, Wei G, Raychaudhuri S, Donovan J, Barretina J, Boehm JS, Dobson J, Urashima M, Mc Henry KT, Pinchback RM, Ligon AH, Cho YJ, Haery L, Greulich H, Reich M, Winckler W, Lawrence MS, Weir BA, Tanaka KE, Chiang DY, Bass AJ, Loo A, Hoffman C, Prensner J, Liefeld T, Gao Q, Yecies D, Signoretti S, Maher E, Kaye FJ, Sasaki H, Tepper JE, Fletcher JA, Tabernero J, Baselga J, Tsao MS, Demichelis F, Rubin MA, Janne PA, Daly MJ, Nucera C, Levine RL, Ebert BL, Gabriel S, Rustgi AK, Antonescu CR, Ladanyi M, Letai A, Garraway LA, Loda M, Beer DG, True LD, Okamoto A, Pomeroy SL, Singer S, Golub TR, Lander ES, Getz G, Sellers WR, Meyerson M. The landscape of somatic copy-number alteration across human cancers. Nature. 2010 Feb 18;463(7283):899-905. doi: 10.1038/nature08822.
- DiAndreth B, Hamburger AE, Xu H, Kamb A. The Tmod cellular logic gate as a solution for tumor-selective immunotherapy. Clin Immunol. 2022 Aug;241:109030. doi: 10.1016/j.clim.2022.109030. Epub 2022 May 11.
- Oh J, Kirsh C, Hsin JP, Radecki KC, Zampieri A, Manry D, Ando Y, Miller S, Chan J, McLeod E, Cunningham KM, Wong LM, Xu H, Kamb A. NOT gated T cells that selectively target EGFR and other widely expressed tumor antigens. iScience. 2024 May 7;27(6):109913. doi: 10.1016/j.isci.2024.109913. eCollection 2024 Jun 21.
Collegamenti utili
Studiare le date dei record
Studia le date principali
Inizio studio (Effettivo)
Inizio studio
Completamento primario (Stimato)
Completamento primario
Completamento dello studio (Stimato)
Completamento dello studio
Date di iscrizione allo studio
Primo inviato
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Effettivo)
Primo Inserito
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento pubblicato
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Parole chiave
- Terapia cellulare
- Cancro
- Cancro ai polmoni
- NSCLC
- Terapia genetica
- EGFR
- Cellula T
- Allogenico
- TNBC
- Tumori solidi
- carcinoma a cellule renali
- Cella CAR-T
- Cancro ai reni
- CRC
- Colorettale
- Cancro delle cellule renali
- Cancro al seno triplo negativo
- RCC
- Carcinoma polmonare non a piccole cellule
- HLA-A2
- Tumori solidi che esprimono EGFR
- Bloccante
Termini MeSH pertinenti aggiuntivi
- Malattie urogenitali
- Neoplasie urogenitali
- Neoplasie per sede
- Malattie urogenitali maschili
- Malattie renali
- Malattie urologiche
- Malattie urogenitali femminili
- Malattie urogenitali femminili e complicanze della gravidanza
- Malattie intestinali
- Malattie delle vie respiratorie
- Neoplasie per tipo istologico
- Neoplasie gastrointestinali
- Neoplasie dell'apparato digerente
- Malattie dell'apparato digerente
- Malattie gastrointestinali
- Neoplasie intestinali
- Malattie del retto
- Malattie polmonari
- Neoplasie della testa e del collo
- Neoplasie, ghiandolari ed epiteliali
- Adenocarcinoma
- Neoplasie delle vie respiratorie
- Neoplasie toraciche
- Malattie del colon
- Malattie della pelle
- Malattie del seno
- Neoplasie urologiche
- Carcinoma
- Carcinoma, broncogeno
- Neoplasie bronchiali
- Carcinoma, cellule squamose
- Neoplasie mammarie
- Malattie della pelle e del tessuto connettivo
- Carcinoma a cellule squamose della testa e del collo
- Neoplasie
- Neoplasie Rettali
- Neoplasie polmonari
- Neoplasie colorettali
- Neoplasie del colon
- Carcinoma, cellule renali
- Carcinoma, polmone non a piccole cellule
- Neoplasie mammarie triplo negativo
- Neoplasie renali
Altri numeri di identificazione dello studio
Altri numeri di identificazione dello studio
- A2B395-101
Piano per i dati dei singoli partecipanti (IPD)
Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?
Descrizione del piano IPD
Study data will be shared within 1 year of study completion.
Periodo di condivisione IPD
Data will be available within 1 year of the completion of the study, the length of time of availability is to be determined.
Tipo di informazioni di supporto alla condivisione IPD
- RSI
Informazioni su farmaci e dispositivi, documenti di studio
Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti
Studia un dispositivo regolamentato dalla FDA degli Stati Uniti
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .